Trials / Completed
CompletedNCT03342690
Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)
DRUG USE INVESTIGATION OF SELARA(REGISTERED). TABLETS(AN INVESTIGATION FOR CHRONIC HEART FAILURE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,165 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 0 Years
- Healthy volunteers
- Not accepted
Summary
Secondary Data Collection Study; Safety And Effectiveness Of Selara Under Japanese Medical Practice
Detailed description
This study will be conducted under the central registration system until the number of subjects who meet the conditions for registration reaches the target number of subjects. The patients will be observed up until Week 52.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eplerenone | In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily. Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions. |
Timeline
- Start date
- 2017-07-05
- Primary completion
- 2020-07-15
- Completion
- 2020-07-15
- First posted
- 2017-11-17
- Last updated
- 2023-07-11
- Results posted
- 2021-06-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03342690. Inclusion in this directory is not an endorsement.